<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="abs0020">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="ulist0010">
   <list-item id="u0010">
    <label>•</label>
    <p id="p0010">This article provides a comprehensive overview of the coronavirus 3CL
     <sup>pro</sup> inhibitors developed from 2010 to 2020.
    </p>
   </list-item>
   <list-item id="u0015">
    <label>•</label>
    <p id="p0015">The SARs, binding modes of peptidomimetic and nonpeptidic inhibitors are comprehensively analysed.</p>
   </list-item>
   <list-item id="u0020">
    <label>•</label>
    <p id="p0020">As anti-coronavirus candidates, reversible covalent PROTACs for 3CL
     <sup>pro</sup> could induce the intracellular degradation of 3CL
     <sup>pro</sup>.
    </p>
   </list-item>
  </list>
 </p>
</abstract>
